Published online April 1, 2008
PEDIATRICS Vol. 121 No. 4 April 2008, pp. e975-e983 (doi:10.1542/peds.2007-2081)
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shulman, D. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shulman, D. I.
Related Collections
Right arrow Therapeutics & Toxicology
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

REVIEW ARTICLE

Use of Aromatase Inhibitors in Children and Adolescents With Disorders of Growth and Adolescent Development

Dorothy I. Shulman, MDa, Gary L. Francis, MD, PhDb, Mark R. Palmert, MD, PhDc, Erica A. Eugster, MDd for the Lawson Wilkins Pediatric Endocrine Society Drug and Therapeutics Committee

a All Children's Hospital, St Petersburg, and Department of Pediatrics, University of South Florida College of Medicine, Tampa, Florida
b Department of Pediatrics, Virginia Commonwealth University, Richmond, Virginia
c Rainbow Babies and Children's Hospital and Department of Pediatrics, Case Western Reserve University, Cleveland, Ohio
d Riley Hospital for Children, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana

Although treatment of children and adolescents who have disorders of growth and adolescent development with aromatase inhibitors is increasingly common, data for or against their use are extremely limited. Precocious puberty, short stature, and gynecomastia are conditions for which inhibition of the enzyme aromatase might prove beneficial to reduce clinical signs of estrogenization and/or estrogen-mediated skeletal maturation. In this report, we summarize the published data regarding the use of aromatase inhibitors in these conditions, and review known and potential benefits, safety concerns, and shortcomings of the available information.

Key Words: aromatase inhibitors • precocious puberty • gynecomastia • short stature

Abbreviations: AI—aromatase inhibitor • CAH—congenital adrenal hyperplasia • CYP19—cytochrome P450 XIX • FMPP—familial male precocious puberty • MAS—McCune-Albright syndrome • GnRH—gonadotropin-releasing hormone • BMD—bone mineral density

Accepted Sep 18, 2007.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 J EndocrinolHome page
I. Mohamed and J. K Yeh
Alfacalcidol prevents aromatase inhibitor (Letrozole)-induced bone mineral loss in young growing female rats
J. Endocrinol., August 1, 2009; 202(2): 317 - 325.
[Abstract] [Full Text] [PDF]